Research ExplorerPublicationsPosterior reversible encephalopathy syndrome

Posterior reversible encephalopathy syndrome

Standard

Posterior reversible encephalopathy syndrome. / Fischer, Marlene; Schmutzhard, Erich.

In: J NEUROL, Vol. 264, No. 8, 08.2017, p. 1608-1616.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Fischer, M & Schmutzhard, E 2017, 'Posterior reversible encephalopathy syndrome', J NEUROL, vol. 264, no. 8, pp. 1608-1616. https://doi.org/10.1007/s00415-016-8377-8

APA

Fischer, M., & Schmutzhard, E. (2017). Posterior reversible encephalopathy syndrome. J NEUROL, 264(8), 1608-1616. https://doi.org/10.1007/s00415-016-8377-8

Vancouver

Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J NEUROL. 2017 Aug;264(8):1608-1616. https://doi.org/10.1007/s00415-016-8377-8

Bibtex

@article{af92459a0e32456db11d4d7febd39589,
title = "Posterior reversible encephalopathy syndrome",
abstract = "The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema. PRES frequently develops in the context of cytotoxic medication, (pre)eclampsia, sepsis, renal disease or autoimmune disorders. The treatment is symptomatic and is determined by the underlying condition. The overall prognosis is favorable, since clinical symptoms as well as imaging lesions are reversible in most patients. However, neurological sequelae including long-term epilepsy may persist in individual cases.",
author = "Marlene Fischer and Erich Schmutzhard",
year = "2017",
month = aug,
doi = "10.1007/s00415-016-8377-8",
language = "English",
volume = "264",
pages = "1608--1616",
journal = "J NEUROL",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "8",

}

RIS

TY - JOUR

T1 - Posterior reversible encephalopathy syndrome

AU - Fischer, Marlene

AU - Schmutzhard, Erich

PY - 2017/8

Y1 - 2017/8

N2 - The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema. PRES frequently develops in the context of cytotoxic medication, (pre)eclampsia, sepsis, renal disease or autoimmune disorders. The treatment is symptomatic and is determined by the underlying condition. The overall prognosis is favorable, since clinical symptoms as well as imaging lesions are reversible in most patients. However, neurological sequelae including long-term epilepsy may persist in individual cases.

AB - The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema. PRES frequently develops in the context of cytotoxic medication, (pre)eclampsia, sepsis, renal disease or autoimmune disorders. The treatment is symptomatic and is determined by the underlying condition. The overall prognosis is favorable, since clinical symptoms as well as imaging lesions are reversible in most patients. However, neurological sequelae including long-term epilepsy may persist in individual cases.

U2 - 10.1007/s00415-016-8377-8

DO - 10.1007/s00415-016-8377-8

M3 - SCORING: Review article

C2 - 28054130

VL - 264

SP - 1608

EP - 1616

JO - J NEUROL

JF - J NEUROL

SN - 0340-5354

IS - 8

ER -